Evidence mapPaperPMID 41751315Full record

ReviewBiomedicines2026

Autophagy in Cancer: Context-Dependent Regulation and Precision Nanomedicine-Enabled Therapeutic Targeting.

Yuzhi Lu, Ang Li, Andong Liu, Meng Li, Meng Wang

Abstract readReview
In one paragraph

Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Autophagy in Ovarian Cancer, an Opportunity or an Additional Threat?International journal of molecular sciences · 2026
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuzhi LuDepartment of Respiratory and Critical Care Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Ang LiDepartment of Human Anatomy, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Andong LiuDepartment of Human Anatomy, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.ORCID 0009-0006-8012-7352
Meng LiInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Meng WangDepartment of Human Anatomy, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.ORCID 0000-0001-6058-718X

Funding

National Natural Science Foundation of China 82403464
6 · The paper itself

Abstract

Autophagy is a highly conserved cellular degradation process essential for maintaining cellular homeostasis, yet its role in cancer is fundamentally context dependent. Increasing evidence indicates that autophagy suppresses tumor initiation by preserving genomic and metabolic integrity, while paradoxically supporting tumor progression, therapy resistance, and immune evasion at advanced stages. This functional duality presents a major challenge for therapeutic targeting and largely reflects the spatiotemporal heterogeneity of autophagy regulation across tumor stages, cancer cell subpopulations, and the tumor microenvironment (TME). In this review, we argue that autophagy-related proteins should be conceptualized as context-dependent therapeutic nodes rather than universally actionable targets. We systematically examine key autophagy regulators, including Beclin-1, p62/SQSTM1, mTOR, and p53, and analyze how their functions are shaped by tumor stage, genetic background, and microenvironmental cues such as hypoxia, immune pressure, and stromal interactions. We further highlight the pivotal role of the TME in determining autophagy dependency and therapeutic vulnerability, providing mechanistic insight into why autophagy modulation without microenvironmental consideration often yields inconsistent outcomes. From a precision medicine perspective, we discuss how nanotechnology-based delivery systems enable spatially and temporally controlled modulation of autophagy, thereby addressing intratumoral heterogeneity and reducing systemic toxicity. By integrating molecular profiling, TME characteristics, and nanomedicine-enabled targeting strategies, this review outlines a rational framework for exploiting autophagy in cancer therapy. Together, these insights provide a foundation for the development of context-aware, autophagy-targeted interventions and advance the pursuit of more effective and personalized cancer treatments.

Indexed as

autophagycancer therapycontext-dependent regulationprecision nanomedicineTME

Identifiers

PMID41751315
PMCPMC12938163

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.